Dec 12 (Reuters) - Novo Nordisk said on Friday the European Medicines Agency's committee had issued a positive opinion for a ...

At present, around 59 million adults worldwide have diabetes, about 64 million are diagnosed with heart failure, and ...

For more than two years it had the entirety of the market for weight-loss drugs to itself. By 2023 sales of Wegovy had ...

While both drugs share the same active ingredient, their positioning, pricing, and regulatory pathways diverge sharply, ...

CHRISTMAS… it’s THE ultimate eating challenge. But for the millions of us reportedly on weight loss jabs, what misery awaits?

Researchers analysed 48 previously-conducted trials which examined the safety and efficacy of GLP-1 drugs on people with type ...

I am bullish on healthcare stocks, especially pharmaceuticals, due to conservative valuations. Check out the healthcare ...

Novo Nordisk announced today that Health Canada has issued marketing authorization with conditions [Notice of Compliance with ...

Novo Nordisk NVO announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) ...

Obesity is a big driver of healthcare spending in South Africa, yet most medical schemes still limit cover for effective ...

The Indian judiciary did well not to let Novo Nordisk extend its exclusive right to sell semaglutide, marketed as Ozempic and ...

We knew that GLP-1 drugs like Ozempic and Wegovy did more than just help control type 2 diabetes and aid weight loss, but the ...